Literature DB >> 30850043

What's New in Atopic Dermatitis.

Yael Renert-Yuval1, Emma Guttman-Yassky2.   

Abstract

The evolving discoveries in atopic dermatitis (AD) shed light on disease pathogenesis and allow better management of patients. Dupiluamab was the first targeted agent approved for AD, proving for the first time AD can be treated with a single cytokine antagonism. Nevertheless, because not all patients respond to dupilumab and AD has a heterogeneous phenotype, more treatment options are much needed. This article reviews recent and exciting developments in AD, because ongoing or pipeline clinical trials for AD will ultimately expand and redefine a novel treatment paradigm for this common disease.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atopic dermatitis; Crisaborole; Dupiluamb; Fezakinumab; GBR 830; JAK inhibitors; Lebrikizumab; Tralokinumab

Mesh：

Substances：

Year:  2019        PMID： 30850043     DOI： 10.1016/j.det.2018.12.007

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN： 0733-8635            Impact factor:   3.478


  9 in total

1.  Duration of neonatal intensive care unit exposure associated with decreased risk of atopic dermatitis.

Authors:  Jennifer J Schoch; Nicole Miranda; Cynthia W Garvan; Reesa L Monir; Josef Neu; Dominick J Lemas
Journal:  Pediatr Dermatol       Date:  2020-10-16       Impact factor: 1.588

Review 2.  Experimental Drugs with the Potential to Treat Atopic Eczema.

Authors:  Kam Lun Ellis Hon; Vivian P Y Chan; Alexander K C Leung
Journal:  J Exp Pharmacol       Date:  2021-05-12

3.  The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults.

Authors:  Yael Renert-Yuval; Ester Del Duca; Ana B Pavel; Milie Fang; Rachel Lefferdink; Jianni Wu; Aisleen Diaz; Yeriel D Estrada; Talia Canter; Ning Zhang; Annette Wagner; Sarah Chamlin; James G Krueger; Emma Guttman-Yassky; Amy S Paller
Journal:  J Allergy Clin Immunol       Date:  2021-01-13       Impact factor: 14.290

4.  Spilanthol Inhibits Inflammatory Transcription Factors and iNOS Expression in Macrophages and Exerts Anti-inflammatory Effects in Dermatitis and Pancreatitis.

Authors:  Edina Bakondi; Salam Bhopen Singh; Zoltán Hajnády; Máté Nagy-Pénzes; Zsolt Regdon; Katalin Kovács; Csaba Hegedűs; Tamara Madácsy; József Maléth; Péter Hegyi; Máté Á Demény; Tibor Nagy; Sándor Kéki; Éva Szabó; László Virág
Journal:  Int J Mol Sci       Date:  2019-09-03       Impact factor: 5.923

Review 5.  Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata.

Authors:  Ana M Montilla; Francisco Gómez-García; Pedro J Gómez-Arias; Jesús Gay-Mimbrera; Jorge Hernández-Parada; Beatriz Isla-Tejera; Juan Ruano
Journal:  Dermatol Ther (Heidelb)       Date:  2019-10-13

Review 6.  Therapeutic New Era for Atopic Dermatitis: Part 2. Small Molecules.

Authors:  Jiyoung Ahn; Yusung Choi; Eric Lawrence Simpson
Journal:  Ann Dermatol       Date:  2021-03-08       Impact factor: 1.444

Review 7.  Selective IL-13 inhibitors for the treatment of atopic dermatitis.

Authors:  Francisca Gonçalves; Egídio Freitas; Tiago Torres
Journal:  Drugs Context       Date:  2021-03-30

8.  Clinical efficacy of fecal microbial transplantation treatment in adults with moderate-to-severe atopic dermatitis.

Authors:  Jacob Mashiah; Tal Karady; Naomi Fliss-Isakov; Eli Sprecher; Dan Slodownik; Ofir Artzi; Liat Samuelov; Eran Ellenbogen; Anastasia Godneva; Eran Segal; Nitsan Maharshak
Journal:  Immun Inflamm Dis       Date:  2021-12-20

9.  Dual Delivery of Fluticasone Propionate and Levocetirizine Dihydrochloride for the Management of Atopic Dermatitis Using a Microemulsion-Based Topical Gel.

Authors:  Saud Almawash; Sheikh Shahnawaz Quadir; Ahmed Al Saqr; Gajanand Sharma; Kaisar Raza
Journal:  ACS Omega       Date:  2022-02-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.